Overexpression of JAK3 in Coronary Arteries of Kawasaki Disease Patients Reveals a New Potential Therapeutic Target
ISEF · 2024 Biomedical and Health Sciences Third Award
Overview
Kawasaki Disease (KD) is a febrile illness predominantly affecting children under five years old and is the leading cause of acquired heart disease in children in developed countries. If KD is not diagnosed and treated on time, it can result in inflammation of coronary arteries (CA) and ultimately a fatal CA aneurysm. This inflammatory process is why KD is deadly, yet much of the KD immune response is unknown. This research sought to identify overexpressed immune proteins in KD CA to gain insight into the KD immune response and determine future targets of treatment. After examining RNA-sequencing results from a previous study, four genes were identified as upregulated in KD CA: Cluster of Differentiation 69 (CD69), Cluster of Differentiation 96 (CD96), Janus Kinase 3 (JAK3), and Integrin Subunit Alpha L (ITGAL). CA tissues from 8 fatal child KD cases and 8 fatal non-KD child controls were stained using immunohistochemistry to detect if high gene expression of CD69, CD96, JAK3, and ITGAL translated into high protein expression in KD patients. Using the Wilcoxon Rank-Sum Test for visual analysis of slides (JAK3: p=0.0013) and logistic regression for ImageJ stain quantification (JAK3: p=0.008), JAK3 was the only protein in both analyses with significantly high expression in KD CA inflammatory cells. Therefore, JAK3 is proposed as a potential KD therapeutic target. JAK3 inhibitors are already employed in treatment for inflammatory illnesses like rheumatoid arthritis, warranting further studies on its application in KD patients unresponsive to current therapies. This research further elucidates the KD immune response by identifying JAK3 as a significantly upregulated protein in the KD immunologic response and proposing JAK3 as a specific target to investigate for KD therapy.
Awards (1)
- Third Award of $1,000 $1,000
Competition history
- ISEF 2024
Resources
Related projects
ISEF · 2022
Assessing the Role of Constitutive JAK/STAT Signaling in Jak2V617F-p53 Post-MPN Leukemia Using a Novel Knock-in/Knock-out Mouse Model of Jak2V617F
CSEF · 2015
DNA Damage Induced by a Novel Drug Cocktail Regulates Chemokine Production in Leukemia through Cytosolic DNA Sensing
CSEF · 2018
Evaluating the Effectiveness of Inhibitors in Reducing Lipopolysaccharide Induced Tumor Necrosis Factor Alpha Expression
AJAS · 2022
Creating an Inflammatory Disease Therapy: Mapping of the 14-3-3zeta and TRAF Interactions
ISEF · 2025
Unlocking CRAC Channel Modulation: Plant Metabolite-Derived ORAI1 Inhibitors Targeting E106 for Rheumatoid Arthritis Treatment Through Combined AI-Derived Virtual Screening Approaches
CSEF · 2018
Tacrolimus-Induced Changes in Fusogenicity of Varicella Zoster Virus
CSEF · 2011
Discovery of the 2,4-Diaminopyrimidine as a Novel Therapeutic Solution for c-Fms and TNF Induced Rheumatoid Arthritis
ISEF · 2022
A Novel Computational Modeling Framework To Analyze Synovial-Tissue Based Drug Targets and Diagnostic Biomarkers in Rheumatoid Arthritis
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair